Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody

被引：0
|
作者：
T Oyama
Y Kagami
M Seto
Y Morishima
机构：
[1] Aichi Cancer Center,Department of Hematology and Chemotherapy
[2] Aichi Cancer Center,Division of Molecular Medicine
来源：
Leukemia | 2001年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1667 / 1667
相关论文
共 50 条
  • [1] Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
    Oyama, T
    Kagami, Y
    Seto, M
    Morishima, Y
    [J]. LEUKEMIA, 2001, 15 (10) : 1667 - 1667
  • [2] Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
    Pescovitz, MD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) : 859 - 866
  • [3] Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan
    Kensei Tobinai
    [J]. International Journal of Hematology, 2002, 76 : 411 - 419
  • [4] Monoclonal antibody therapy for B-Cell lymphoma: Clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
    Tobinai, K
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (05) : 411 - 419
  • [5] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
    Hotta, T
    [J]. ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
  • [6] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
    Czuczman, MS
    Grillo-López, AJ
    White, CA
    Saleh, M
    Gordon, L
    LoBuglio, AF
    Jonas, C
    Klippenstein, D
    Dallaire, B
    Varns, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 268 - 276
  • [7] Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with Rituximab, a chimeric Anti-CD20 monoclonal antibody
    Soda, R
    Costanzo, A
    Cantonetti, M
    Orlandi, A
    Bianchi, L
    Chimenti, S
    [J]. ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 207 - 208
  • [8] Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
    Foran, JM
    Cunningham, D
    Coiffier, B
    Solal-Celigny, P
    Reyes, F
    Ghielmini, M
    Johnson, PWM
    Gisselbrecht, C
    Bradburn, M
    Matthews, J
    Lister, TA
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 117 - 121
  • [9] T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma
    Vincent-Salomon, A
    Mathiot, C
    MacIntyre, E
    Girre, V
    Fourquet, A
    Mercier, C
    Fréneaux, P
    Dumont, J
    Decaudin, D
    [J]. LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 387 - +
  • [10] CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
    Massengale, WT
    McBurney, E
    Gurtler, J
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) : 441 - 443
12345